4D Molecular Therapeutics Inc (FDMT)
9.96
-0.38
(-3.68%)
USD |
NASDAQ |
Oct 04, 16:00
9.98
+0.02
(+0.20%)
After-Hours: 20:00
4D Molecular Therapeutics SG&A Expense (Annual): 36.49M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 36.49M |
| December 31, 2022 | 32.91M |
| December 31, 2021 | 28.01M |
| December 31, 2020 | 17.24M |
| Date | Value |
|---|---|
| December 31, 2019 | 13.90M |
| December 31, 2018 | 6.167M |
| December 31, 2017 | 3.489M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
13.90M
Minimum
2019
36.49M
Maximum
2023
25.71M
Average
28.01M
Median
2021
SG&A Expense (Annual) Benchmarks
| Johnson & Johnson | 20.11B |
| Regeneron Pharmaceuticals Inc | 2.631B |
| Journey Medical Corp | 43.91M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 12.27M |